ArticleFrontiers in pharmacology2026
Integrated network toxicology and multi-omics profiling reveal cell cycle, DNA damage repair, and metabolic alterations in cyclophosphamide-induced premature ovarian insufficiency.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cyclophosphamide (CTX)-induced chemotherapy injury is a leading iatrogenic cause of premature ovarian insufficiency (POI) and a major barrier to fertility preservation. Yet the systems-level mechanisms underlying its reproductive toxicity remain poorly defined. Methods: An integrated network toxicology framework incorporating machine learning and Mendelian randomization (MR) was applied to identify candidate targets, evaluate genetic associations, and establish a predictive model. Ovarian transcriptomic and metabolomic profiling, together with Results: Integrated bioinformatic analyses and machine learning prioritized six candidate targets associated with CTX-induced ovarian injury, with PLS regression consistently identified as the optimal predictive model. SHAP analysis revealed CXCL1 and COL4A4 as the major contributors to model prediction. MR supported genetic associations between genetically predicted CXCL1/COL4A4 expression and POI risk. Immunohistochemical validation confirmed protein expression patterns consistent with transcriptomic findings. Multi-omics profiling revealed a convergent ovarian injury signature characterized by impaired cell-cycle regulation (G2/M checkpoint), defective DNA damage repair and mitotic function (mitotic spindle), enhanced apoptotic signaling, and coordinated suppression of folate metabolism, ubiquinone biosynthesis, and cytochrome P450-mediated drug metabolism pathways. Single-cell-based Conclusion: This study shows that CTX-induced ovarian injury is accompanied by coordinated alterations in immune-inflammatory signaling, cell-cycle and DNA damage responses, and metabolic homeostasis. CXCL1 and COL4A4 were prioritized as candidate biomarkers associated with POI risk, providing potential targets for further mechanistic investigation and fertility-preserving interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.